Cornell University

Sunghee Cho

Hazel Szeto

Shaoyi Liu

Shaoyl Liu

Yi Bao

Eunhee Kim

Hazel H Szeto

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3 pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2a is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1.

Methods for reducing CD36 expression

The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower blood glucose levels, and treat and prevent metabolic syndrome, pre-diabetes and diabetes, and lower plasma cholesterol levels and decrease fat deposit in the liver. CD36 antagonists, including SAB or its metabolites, such as RA and DSS, are useful for these purposes.

CD36 inhibition to control obesity and insulin sensitivity

The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3 pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2a is the largest number that is less than or equal to p+1, except that when a is 1, pmay also be 1.

The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p) and the total number of amino acid residues (r) wherein 3pis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p) wherein 2is the largest number that is less than or equal to p&#x2212;1, except that when a is 1, pmay also be 1.

Growing community of inventors

Scarsdale, NY, United States of America

Sunghee Cho